Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)

SIMPLE SUMMARY: Treatment of metastatic renal cell carcinoma (mRCC) remains a challenge due to the lack of biomarkers indicating the optimal drug for each patient. This study analyzed blood samples of patients with predominant clear cell mRCC who were treated with the mTOR inhibitor everolimus after...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeuschner, Philip, Hölters, Sebastian, Stöckle, Michael, Seliger, Barbara, Mueller, Anja, Bachmann, Hagen S., Grünwald, Viktor, Christoph, Daniel C., Stenzl, Arnulf, Grimm, Marc-Oliver, Brüning, Fabian, Goebell, Peter J., Augustin, Marinela, Roos, Frederik, Harde, Johanna, Benz-Rüd, Iris, Staehler, Michael, Junker, Kerstin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199288/
https://www.ncbi.nlm.nih.gov/pubmed/34070677
http://dx.doi.org/10.3390/cancers13112594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199288/
https://www.ncbi.nlm.nih.gov/pubmed/34070677
http://dx.doi.org/10.3390/cancers13112594

Ejemplares similares